Skip to main content
. Author manuscript; available in PMC: 2017 Apr 1.
Published in final edited form as: Curr Opin Endocrinol Diabetes Obes. 2016 Apr;23(2):157–164. doi: 10.1097/MED.0000000000000237

Figure 2.

Figure 2

Demonstration of residual risk of elevated Lp(a) in the JUPITER, AIM-HIGH and LIPID trials, in setting of very aggressive statin therapy and well-controlled LDL-C levels. The Forest plot shows a study level meta-analysis of these 3 recent reports from these trials. Shown are baseline Lp(a) levels of AIM-HIGH niacin and placebo arms, baseline Lp(a) levels in the LIPID trial and baseline Lp(a) levels in the entire JUPITER arm and in the group receiving rosuvastatin and the hazard ratio of the highest quartile and recurrent CVD events.